Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 01 2020 - 7:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of December 2020
Commission
File Number 001-38370
CollPlant
Biotechnologies Ltd.
(Exact
name of registrant as specified in its charter)
4
Oppenheimer St, Weizmann Science Park
Rehovot
7670104, Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
The
text under the headings “Third Quarter 2020 Financial Results on U.S. GAAP basis”, “Third Quarter 2020 Financial
Results on Non-U.S. GAAP Basis”, the accompanying consolidated financial statements and “Forward Looking Statements”
of the press release attached to this Form 6-K are hereby incorporated by reference into the registrant’s Registration Statements
on Form S-8 (File No. 333-229163 and 333-248479) and Form F-3 (File No. 333-229486, 333-228054 and 333-238731), to be a part thereof
from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On
December 1, 2020, CollPlant Biotechnologies Ltd. issued a press release entitled “CollPlant Biotechnologies Reports Third
Quarter (Q3) 2020 Financial Results and Provides Business Update”.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
|
|
|
Date:
December 1, 2020
|
By:
|
/s/
Eran Rotem
|
|
|
Name:
|
Eran
Rotem
|
|
|
Title:
|
Deputy
CEO and Chief Financial Officer
|
2
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024